PharmaLegacy of Shanghai Forms Alliance with Normalline

PharmaLegacy Labs, a Shanghai preclinical CRO, has formed a strategic alliance with Normalline of Beijing. Normalline offers regulatory guidance for medical device companies seeking entry to China's market. The two companies positioned the alliance as a combination of Normalline's regulatory device expertise, which has a 100% approval success rate since its founding in 2008, with PharmaLegacy's animal models and bone/orthopedics capabilities. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.